Login / Signup
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
Send us Feedback
GlaxoSmithKline (GSK)
SUMMARY
BULLS
BEARS
DATA CENTRAL
STOCK CHART
OPERATING METRICS
REVENUE SOURCES
BALANCE SHEET
INCOME STMT
CASH FLOW
Key Metrics for GSK as compared to
Top Competitors
Drug Manufacturers - Major
Drug Manufacturers
Pharma & Healthcare
All values TTM unless otherwise noted (*)
INDUSTRY METRICS (
See all
)
Revenue
►
25.1B
HIGH
R&D Expense
►
3.68B
AVG
R&D/Sales Ratio
►
15.1%
AVG
Number of Drugs
►
210
HIGH
Total Drug Recalls
►
1.00
LOW
Number of Drug Approvals
►
15.0
HIGH
Drug Applications
►
9.00
AVG
Revenue
Number of Drugs
Number of Drug Recalls
New Drug Applications
Number of Drug Approvals
Number of Drugs in Phase I
Number of Drugs in Phase II
Number of Drugs in Phase III
R&D/Sales Ratio
Research and Development Expense
Net Income
Operating Income
INCOME STATEMENT (
See all
)
Revenue
►
25.1B
HIGH
EBITDA
►
8.84B
AVG
Net Income
►
4.26B
AVG
Revenue Growth
►
-43.3%
VERY LOW
Net Income Growth
►
-53.2%
LOW
Operating Margin
►
22.5%
AVG
Net Margin
►
17.1%
AVG
Revenue, Net Income, and Net Margin
Revenue, Gross Profit, and Gross Margin
Operating Income
Ebit
Income Before Taxes
Net Income from Continuing Ops
Interest vs Continuing Income
Interest Coverage
Operating Expenses
Research & Development
SG&A
Amortization & Depreciation
BALANCE SHEET (most recent quarter) (
See all
)
Debt / Equity
►
3.43
VERY HIGH
Current Ratio
►
1.56
LOW
Quick Ratio
►
1.18
LOW
Interest Coverage Ratio
►
9.46
AVG
Book Value Per Share
►
5.24
Cash Per Share
►
3.65
Loading...
STOCK SUMMARY
Open
42.47
Day Range
40.94
-
41.56
52 Week Range
27.15
-
42.18
Volume
1.39M
Avg Volume (3 mo)
1.39M
Shares Outstanding
2.80B
Market Cap
118B
VALUATION
Price to Earnings (P/E)
►
27.2
VERY HIGH
Price to Book (P/B)
►
7.85
VERY HIGH
Price to Sales (P/S)
►
4.65
AVG
Return on Assets (ROA)
►
7.9%
AVG
Return on Equity (ROE)
►
30.4%
AVG
EV/EBITDA
►
17.1
HIGH
Dividend Yield
4.8%
VERY HIGH
ANALYST RECOMMENDATIONS
OWNERSHIP
Held by institutions
7.7%